Efficacy and safety of humanized CD19 CAR-T as a salvage therapy for recurrent CNSL of B-ALL following murine CD19 CAR-T cell therapy
Sign Up to like & getrecommendations! Published in 2021 at "Oncology Letters"
DOI: 10.3892/ol.2021.13049
Abstract: The present study aimed to compare the differences between the humanized CD19 chimeric antigen receptor (CAR)-T cell therapy and the murine CD19 CAR-T therapy in recurrent B-acute lymphoblastic leukemia (B-ALL). A 62-year-old male patient who… read more here.
Keywords: murine cd19; therapy; humanized cd19; car ... See more keywords